TWD 179.0
(-1.65%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 4.72 Billion TWD | -10.77% |
2022 | 5.29 Billion TWD | 69.17% |
2021 | 3.12 Billion TWD | 40.66% |
2020 | 2.22 Billion TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 4.97 Billion TWD | 5.22% |
2024 Q2 | 5.18 Billion TWD | 4.22% |
2023 Q4 | 4.72 Billion TWD | 1.48% |
2023 FY | 4.72 Billion TWD | -10.77% |
2023 Q1 | 4.99 Billion TWD | -5.73% |
2023 Q3 | 4.65 Billion TWD | -4.84% |
2023 Q2 | 4.89 Billion TWD | -1.98% |
2022 Q4 | 5.29 Billion TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 3.85 Billion TWD | -22.504% |
Maxigen Biotech Inc. | 1.49 Billion TWD | -216.41% |
SciVision Biotech Inc. | 2.16 Billion TWD | -118.685% |
Bionime Corporation | 5.3 Billion TWD | 10.878% |
Pegavision Corporation | 13.85 Billion TWD | 65.914% |